Biocon Limited , a leading biopharmaceutical company, held its 47th Annual General Meeting (AGM) on August 8, 2025, where shareholders approved significant board re-appointments. The meeting, conducted through video conferencing, saw the re-election of two prominent directors, reinforcing the company's leadership structure.

Key Re-appointments

Shareholders gave their nod to the re-appointment of Prof. Ravi Rasendra Mazumdar as a Director liable to retire by rotation. Prof. Mazumdar, who serves as a University Research Chair Professor at the University of Waterloo, Canada, brings valuable academic and research expertise to Biocon's board. Notably, he is the father of Eric Vivek Mazumdar and the brother of Kiran Mazumdar-Shaw, Biocon's Executive Chairperson.

In another significant move, Ms. Naina Lal Kidwai secured re-appointment as an Independent Director for a second term of five consecutive years, extending from August 8, 2025, to August 7, 2030. Ms. Kidwai's re-election underscores the company's commitment to maintaining strong corporate governance. Her extensive experience includes her current role as Chairperson and Senior Advisor of Rothschild & Co India, as well as board positions in several prominent companies such as Holcim SA, Gland Pharma Limited, Nayara Energy Limited, and UPL Limited.

Corporate Governance and Compliance

Biocon emphasized that both re-appointed directors have not been debarred from holding directorship positions by the Securities and Exchange Board of India (SEBI) or any other regulatory authority. This affirmation highlights the company's adherence to regulatory compliance and corporate governance standards.

AGM Proceedings

The 47th AGM, held virtually, covered a range of important matters beyond the director re-appointments. Kiran Mazumdar-Shaw, Executive Chairperson of Biocon, delivered a comprehensive speech highlighting the company's performance and strategic initiatives.

Key points from the Chairperson's address included:

• Biocon's focus on 'Accelerating Reach' to expand access to essential medicines globally
• Strategic capital investments made in FY25 to support long-term growth
• Expansion of manufacturing capacity and enhancement of R&D capabilities
• Strong performance in the Biosimilars business, which grew by 15% year-on-year
• Launch of generic Liraglutide in the UK, marking Biocon's entry into the 'diabesity' therapeutic area
• Approval of Biosimilar Insulin Aspart as an Interchangeable product in the U.S.
• Successful fundraising efforts, including a ₹4,500 crore Qualified Institutions Placement (QIP)

Financial Highlights

The AGM also touched upon Biocon's financial performance for Q1 FY26:

Future Outlook

Biocon's management expressed confidence in the company's growth trajectory, citing recent product launches, approvals, and strategic investments. The company remains focused on scaling commercialized products, deepening its presence in key markets, and preparing for future launches to drive sustainable and profitable growth.

The re-appointment of experienced directors like Prof. Mazumdar and Ms. Kidwai, coupled with the company's strong financial performance and strategic initiatives, positions Biocon to continue its mission of expanding access to life-saving medicines globally while creating long-term value for stakeholders.

Biocon Limited , a leading global biopharmaceuticals company, has announced robust financial results for the first quarter of fiscal year 2026, demonstrating significant growth across its key business segments.

Financial Highlights

Biocon's consolidated revenue from operations for Q1 FY26 reached Rs 3,942.00 crore, marking a 15% year-on-year increase. The company's EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) grew by 19% to Rs 829.00 crore, with an EBITDA margin of 21%. Core EBITDA, which excludes R&D expenses, licensing, forex, and other items, stood at Rs 1,003.00 crore, up 11% from the previous year, with a margin of 25%.

Profit Before Tax (PBT) before exceptional items saw a substantial rise of 72% to Rs 97.00 crore, while Net Profit before exceptional items increased by 342% to Rs 31.00 crore.

Segment Performance

Biosimilars

The Biosimilars segment, operated by Biocon Biologics, emerged as the star performer with an 18% year-on-year revenue growth, reaching Rs 2,458.00 crore. This segment's EBITDA rose by 36% to Rs 645.00 crore, with a margin improvement of 300 basis points sequentially.

Contract Research, Development & Manufacturing Organization (CRDMO)

The CRDMO segment, represented by Syngene, reported an 11% year-on-year growth with revenues of Rs 875.00 crore. EBITDA for this segment increased by 19% to Rs 224.00 crore.

Generics

The Generics business showed steady growth with a 6% year-on-year increase in revenue, reaching Rs 697.00 crore. This growth was primarily driven by recent drug product launches and higher API volumes.

Key Developments

Biocon achieved several milestones during the quarter:

• Received U.S. FDA approval for Kirsty™ (bAspart), an interchangeable biosimilar insulin aspart.
• Launched Yesafili™, a biosimilar aflibercept, in Canada, marking the company's entry into ophthalmology and its 10th biosimilar globally.
• Obtained regulatory approvals for biosimilar denosumab products in Europe and the UK.
• Successfully raised Rs 4,500.00 crore through a Qualified Institutions Placement (QIP), strengthening the company's balance sheet.

Management Commentary

Kiran Mazumdar-Shaw, Chairperson of Biocon Group, stated, "Biocon opened FY26 with a strong performance, driven by continued gains in Biosimilars and CRDMO, and a steady showing in Generics. The recent QIP has strengthened our balance sheet and enables us to increase our ownership in Biocon Biologics by facilitating the exit of structured equity investors, aligning capital structure with long-term strategic priorities."

Shreehas Tambe, CEO & Managing Director of Biocon Biologics Limited, commented on the Biosimilars segment's performance, saying, "As we enter the 'Accelerate' phase, we are confident in our ability to scale, deepen market presence, and deliver sustained growth."

Outlook

With a strong start to FY26, Biocon appears well-positioned for continued growth. The company's focus on expanding its biosimilars portfolio, enhancing manufacturing capabilities, and strategic investments in scientific capabilities are expected to drive long-term value creation.

Biocon's performance in Q1 FY26 reflects its robust business model and successful execution of growth strategies across its diverse portfolio of biopharmaceutical products and services.